AgenT-797 Combination in the Second-line Setting for Gastric, Esophageal Cancers
By Yelena Janjigian, MD - Last Updated: March 19, 2025Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, provides insight on a phase 2 trial evaluating AgenT-797 in combination with botensilimab, balstilimab, ramucirumab, and paclitaxel in the second-line setting for the treatment of gastric, esophageal, and gastroesophageal junction cancer.
Advertisement
Dr. Janjigian discusses how the agent – created with invariant natural killer t-cells – works in tandem with other therapies, and the positive results of this early-phase trial so far.
View Dr. Janjigian’s further comments on the 3-year follow-up results of CheckMate 649.
Advertisement
Related Posts
Researchers evaluated the use of mFOLFIRINOX for the treatment of patients with resectable pancreatic adenocarcinoma.
Dr. Christopher Lieu shares his top liver-directed therapies for metastatic colorectal cancer with liver involvement.
Dr. Christopher Lieu shares his list of top targeted therapies for metastatic colorectal cancer.
In a systematic review, researchers found that several anti-HER2 therapies may benefit patients with biliary tract cancers.
The guideline includes recommendations for the management of carcinoid syndrome and carcinoid heart disease.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.